NCT04862962View on ClinicalTrials.gov

Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia

CompletedOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

January 15, 2022

Study Completion Date

February 15, 2022

Conditions
Dyslipidemias
Interventions
DRUG

Rosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dose

Oral Tablets 10 mg/10 mg or 20 mg/10 mg

Trial Locations (1)

11000

Laboratorio Silanes, S.A. de C.V., Mexico City

All Listed Sponsors
lead

Laboratorios Silanes S.A. de C.V.

INDUSTRY

NCT04862962 - Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia | Biotech Hunter | Biotech Hunter